MorphoSys: Accelerating The Long Transformation

Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.

In contrast to much of the transformation that can occur in the biotech world, MorphoSys AG’s strategic shift from provider of antibody technologies to developer of proprietary antibody therapeutics has occurred at a comparably glacial pace.

Years ago – around the time it signed a blockbuster antibody discovery deal with Novartis AG in 2007 –...

More from Global Vision

More from In Vivo